Description
Background:
Vunakizumab is a monoclonal antibody that specifically targets the interleukin-4 receptor alpha (IL-4R). IL-4R is involved in the signaling pathway of interleukin-4 and interleukin-13, which are cytokines associated with inflammation and immune responses. By binding to IL-4R, vunakizumab inhibits the interaction between IL-4 and IL-13 with their receptor, thereby modulating the immune response and potentially reducing inflammation. This mechanism of action suggests that vunakizumab may have therapeutic applications in conditions driven by IL-4 and IL-13, such as certain allergic and autoimmune diseases. Vunakizumab has been studied in clinical trials for various conditions, including atopic dermatitis, asthma, and eosinophilic esophagitis.
Intended Use:
For Estimation of Vunakizumab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!